BPC-157 vs TB-500
Both are discussed for recovery, but BPC-157 has a larger preclinical literature while TB-500 fragment has even less direct human drug-exposure evidence. Neither has established routine human efficacy for musculoskeletal injury.
| Attribute | BPC-157 | TB-500 |
|---|---|---|
| Human evidence | Human evidence remains extremely limited. A 2025 systematic review found 35 preclinical studies and only one clinical study; a later retrospective real-world preprint cannot establish efficacy. GI and injury-healing claims remain dominated by animal/preclinical research. | FDA reports no identified human drug-product exposure for the TB-500 fragment. A 2026 rat Achilles-tendon study provides animal evidence for a material the authors call TB-500, but the inspected paper does not independently establish that it was the FDA-defined LKKTETQ fragment. A fictional/example registry record is not counted as human evidence. |
| Research focus | Musculoskeletal injury, gastrointestinal and wound-healing research | Wound/tissue-repair research claims |
| Regulatory status | Not FDA-approved; FDA has highlighted safety-information gaps for compounded BPC-157. | Not FDA-approved; FDA has reviewed TB-500-related substances in the compounding context and highlights safety/data gaps. |
| Route / formulation | Results from animal models cannot be presented as proven human healing effects. Research-grade product quality varies. | TB-500 fragment evidence must remain separate from full-length thymosin beta-4 and from fictional/example registry content. |
Why these are compared
These compounds appear in the injury & recovery evidence landscape, but they are not interchangeable. BPC-157 is synthetic 15-amino-acid peptide studied in musculoskeletal injury, gastrointestinal and wound-healing research; TB-500 is synthetic fragment of thymosin beta-4 studied in wound/tissue-repair research claims. The purpose of this page is to compare the evidence base, not to recommend one compound over another.
Evidence maturity
BPC-157: Primarily preclinical / extremely limited human evidence across injury and GI claims.
TB-500: Identity-qualified preclinical evidence; confirmed human drug-exposure gap.
The table above gives the fuller human-evidence, regulatory and formulation context. Open the individual profiles for study-level records, limitations and source provenance.
What this comparison can and cannot establish
No direct head-to-head human efficacy trial identified. Cross-study comparisons can be distorted by differences in population, route, formulation, dose, duration and endpoint. WhichPeps therefore does not turn indirect comparisons into a treatment recommendation or name a winner. A well-designed head-to-head human trial using comparable populations and clinically relevant outcomes would reduce uncertainty. For any compound with little or no established human exposure, published human safety and efficacy data would also materially change the evidence picture.